商品名：CellCept
Mycophenolate is a prodrug metabolized to mycophenolic acid (MPA). It is used to suppress immunity for transplantation and for treatment of immune-mediated diseases. Mycophenolate, when metabolized to mycophenolic acid, inhibits inosine monophosphate dehydrogenase (IMPDH), which is an important enzyme for the de novo synthesis of purines in immune cells, especially stimulated lymphocytes. T and B lymphocytes are critically dependent on de novo synthesis of purine nucleotides. Therefore it effectively suppresses lymphocyte proliferation and decreases antibody synthesis by B-cells. In people it
Mycophenolate is used to treat immune-mediated diseases in animals. In dogs, mycophenolate has been used on a limited basis to treat some immune- mediated diseases. According to pharmacokinetic studies with mycophenolate in dogs, the elimination rate was rapid (half-life less than 1 hour), which may require frequent dosing in dogs for successful therapy. For treatment of pemphigus foliaceous, it was given at a dose of 22-39 mg/kg/day divided into three treatments. It was well-tolerated, but only three out of eight dogs completed the study and were improved. Azathioprine is more commonly used a
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
先核對前驅藥、活性代謝物、鹽型、精確商品、劑型、濃度與法域。 確認物種、診斷、疾病嚴重度、感染風險、先前治療與全部共同免疫抑制藥。 由獸醫師個別規劃血球、器官功能、感染、臨床反應及毒性追蹤。 繁殖、懷孕、哺乳、幼齡、處理暴露與家庭成員風險須個別評估。 疑似胃腸傷害、血球抑制、感染、過敏或神經異常需立即重新評估。 系統不得自動產生劑量、處方、替代、調整、補用、停藥、救援或調製指示。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
renal